Focus: Zai Lab is a publicly traded biotech company focused on small molecule oncology and immunology therapies, with a diversified pipeline spanning 40 clinical programs across multiple therapeutic areas.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Zai Lab to get notified when they start hiring — the background below is worth knowing for when they do.
Lead commercial product with dual formulations and patent protection through 2033-2036, providing near-term revenue foundation.
Help build intelligence for Zai Lab
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Zai Lab's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic product post-loss of exclusivity, contributing minimal strategic value.
Generic corticosteroid with limited differentiation and shrinking commercial relevance.
Zai Lab wins FDA fast track status for cancer drug Zocilurtatug Pelitecan - MSN
Zai Lab wins FDA fast track status for cancer drug Zocilurtatug Pelitecan MSN
BRIEF: Zai Lab revenue falls on fading sales for its best-selling drug - thebambooworks.com
BRIEF: Zai Lab revenue falls on fading sales for its best-selling drug thebambooworks.com
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO - Fierce Pharma
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO Fierce Pharma
AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent - Fierce Biotech
AACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascent Fierce Biotech
Zai Lab stock rises on positive trial data for cancer drug - Investing.com
Zai Lab stock rises on positive trial data for cancer drug Investing.com
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study - Pharmaceutical Technology
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study Pharmaceutical Technology
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Efficacy, Safety, and Tolerability of Subcutaneous Efgartigimod PH20 in Chinese Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Prespecified Subpopulation Analysis of the Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase II ADHERE Trial.
Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo